Investors in TMT

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and create value out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

The Morningside Group Limited is a private equity and venture capital firm specializing in early stage. It seeks to make investments in machinery manufacturing, high-tech, life science companies formed around new technologies, media, the Internet, biotechnology, telecommunication, life science, entertainment, consumer, education, and clean tech sectors. It seeks to invest in companies based in North America, Europe, and Asia Pacific, where its particular focus is on China. The Morningside Group Limited was founded in 1986 and is based Hong Kong with additional offices in Shanghai, China; Beijing, China; and Boston, United States.

OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.

YFM Equity Partners LLP is a venture capital and private equity firm specializing in investments in growth capital, recapitalization, development, expansion, management buy outs, and management buyins. The firm seeks to invest in mid and late venture, mature, and emerging growth companies. It seeks to invest in firms which are not involved in primary industries. The firm invests in small and medium sized entrepreneurs (SMEs) and companies across a range of sectors and has a particular interest in energy, materials, manufacturing, consumer staples, consumer electronics, healthcare, financials, business services, information technology, telecommunications, utility, software and services, internet, computer hardware, computers and peripherals, electronic equipments, instruments and components, retail roll-outs, utilities, consumer brands, and companies with proprietary technology. It seeks to invest in companies based in United Kingdom including; South-West, Yorkshire with a focus on North Yorkshire; South Yorkshire; West Yorkshire, Somerset, Wiltshire, Humberside, and North Lincolnshire. The firm also seeks to invest in North West region with a focus on England including Cheshire, Cornwall, Cumbria, Devon, Dorset, Gloucestershire, Greater London, Greater Manchester, Lancashire, and Merseyside. It also invests in the United States. It seeks to invest between £0.1 million ($0.19 million) and £10 million ($14.51 million) of equity in companies with sales value between £5 million ($0.19 million) and €50 million ($71.36 million). The firm seeks to provide £10 million ($16.13 million) for late stage and buyout investments. It seeks to take Board membership in its portfolio company. The firm prefers to hold majority stake. It seeks to exit its investments within five years through sale or listing. YFM Equity Partners Limited was founded in 1982 and is based in Leeds, United Kingdom with additional offices in London, Birmingham, Manchester, and Sheffield in United Kingdom.

As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

Alexandria Venture Investments is a strategic venture capital arm of Alexandria Real Estate Equities. Alexandria Venture Investments provides long-term strategic investment capital to innovative life science and technology entities developing breakthrough technologies and therapies. Leveraging their experience and in-depth understanding of the life science and technology industries, their long-term relationships with leading investors, and their world-class scientific advisory network, they are uniquely positioned to fund seed-, early-, and growth-stage companies.

Hatteras Discovery is a venture capital firm specializing in early and seed stage investments. It seeks to invest in the life sciences and healthcare sectors with a focus on the following key therapeutic areas: ophthalmology, cardiovascular, pulmonary, anti-infectives, oncology, immunology, and orphan diseases. It will invest in North Carolina. It targets investing between $0.25 million and $1 million in portfolio companies. Hatteras Discovery was founded in August 2011 and is based in Durham, North Carolina. It operates as a subsidiary of Hatteras Venture Partners.

Good health is vital to all of them , and finding sustainable solutions to the most pressing health care challenges of their world cannot wait. That's why they at Pfizer are committed to applying science and their global resources to improve health and well-being at every stage of life. They strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them. They have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.

Stonebridge Ventures is a venture capital firm. The firm operates as a subsidiary of Stonebridge Capital Inc. It considers secondary investments. Stonebridge Ventures was founded in 2017 and is based in Seoul, South Korea.

Wellington Management Company is a Boston based institutional investment advisor firm. The firm invests in global equity, fixed income, currency and commodity markets, multi-strategy, specialty and alternative investments. The firm offers separate accounts and a wide range of commingled vehicles that include both US and non-US domiciled portfolios. The company was founded in 1928.